Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEProdigiosinCat.No.:HY-100711CASNo.:82-89-3Synonyms:Prodigiosine分?式:C??H??N?O分?量:323.43作?靶點:Bacterial;Apoptosis;Wnt;Fungal;Parasite作?通路:Anti-infection;Apoptosis;StemCell/Wnt儲存?式:Powder-20°C3yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:25mg/mL(77.30mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM3.0919mL15.4593mL30.9186mL5mM0.6184mL3.0919mL6.1837mL10mM0.3092mL1.5459mL3.0919mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。BIOLOGICALACTIVITY?物活性Prodigiosin(Prodigiosine)，?種天然的紅?素，?種具有?物活性的次?代謝產(chǎn)物。ProdigiosinWnt/β-catenin途徑的有效抑制劑。Prodigiosin具有抗，抗真，抗原?動物，抗瘧疾，免疫抑制和抗癌特性。體外研究Prodigiosin(25-500nM;24hours)treatmentreducestheviabilityofbreastcancercells,withIC50valuesat1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE48hof62.52nMinMDA-MB-231cellsand261.2nMinMDA-MB-468cells[1].Prodigiosin(25-500nM;24hours)treatmentsignificantlyreducesthelevelsofphosphorylatedLRP6andDVL2,activeβ-catenin,andtotalβ-catenin.ProdigiosinnoticeablyinhibitsthephosphorylationofGSK3βatSer9inHEK293Tcells,whichisindicativeofanincreaseinGSK3βactivity[1].Prodigiosincaninhibitproliferationandinduceapoptosisinbreastcancercells[1].Prodigiosin(25-500nM;24hours)treatmentdose-dependentlyblocksWntsignalingactivatedbyWnt1,Wnt3,Wnt1/LRP6,Wnt3/LRP6,andDishevelled2(DVL2)intransfectedHEK293Tcells.ProdigiosintreatmentinhibitsWnt3A-CM-inducedtranscriptioninadose-dependentmanner.ProdigiosininhibitstranscriptionoftheSuperTopFlashreporteractivatedbyeitherWnttransfectionorWnt3Atreatment[1].WhenappliedtoculturesofchytridfungiBatrachochytriumdendrobatidisandB.salamandrivorans,Prodigiosincausessignificantgrowthinhibition,withMICvaluesof10μMand50μM,respectively[2].CellProliferationAssay[1]CellLine:MDA-MB-231andMDA-MB-468cellsConcentration:10nM,25nM,50nM,100nM,250nM,500nM,1000nM,2500nM,5000nMIncubationTime:24hours,48hoursResult:Reducedtheviabilityofbreastcancercells,withIC50valuesat48hof62.52nMinMDA-MB-231cellsand261.2nMinMDA-MB-468cells.WesternBlotAnalysis[1]CellLine:HEK293TcellsConcentration:50nM,100nM,250nM,500nMIncubationTime:24hoursResult:SignificantlyreducedthelevelsofphosphorylatedLRP6andDVL2,activeβ-catenin,andtotalβ-catenin.體內(nèi)研究Prodigiosin(5mg/kg;intraperitonealinjection;twiceweekly;for3weeks)treatmentsignificantlyinhibitstumorgrowth.ProdigiosintreatmentdecreasestumorcelldensityandexpressionoftheproliferationmarkerKi-67[1].AnimalModel:FemaleBALB/cnudemiceinjectedwithMDA-MB-231cells[1]Dosage:5mg/kgAdministration:Intraperitonealinjection;twiceweekly;for3weeksResult:Significantlyinhibitedtumorgrowthinmice.REFERENCES2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE[1].WoodhamsDC,etal.Prodigiosin,Violacein,andVolatileOrganicCompoundsProducedbyWidespreadCutaneousBacteriaofAmphibiansCanInhibitTwoBatrachochytriumFungalPathogens.MicrobEcol.2018May;75(4):1049-1062.[2].WangZ,etal.ProdigiosininhibitsWnt/β-cateninsignalingandexertsanticanceractivityinbreastcancercells.ProcNatlAcadSciUSA.2016Nov15;113(46):13150-13155.McePdfHeightCaution:Producthasno